CLINICAL ROLE -
Data From VOYAGER PAD Can Help Underdiagnosed, Untreated Individuals with Peripheral Arterial Disease
Ince describes why patients who are considered fragile are often underdiagnosed and undertreated, and that the VOYAGER PAD analyses can encourage the treatment of the fragile population.
Watch
Abelacimab Demonstrates Significant Reduction in Bleeding vs Rivaroxaban in Patients With Atrial Fibrillation
The AZALEA-TIMI 71 randomized trial evaluated the safety and tolerability of 2 blinded doses of the novel factor XI inhibitor abelacimab compared with open-label rivaroxaban.
Read More
Rivaroxaban Demonstrates Favorable Benefit-Risk Profile in Fragile Populations with Peripheral Arterial Disease
Bonaca also notes that pharmacists can play a key role in educating patients and clinicians about the appropriate use and dosing of antithrombotic drugs for vascular protection.
Upcoming Phase 3 Trials to Evaluate Efficacy, Safety of Milvexian in Patients with Cardiovascular Conditions
Harrington discusses how the performance of milvexian in prior phase 2 trials focused on different patient populations creates the foundation for future research.
Phase 3 Trial Demonstrates Benefits to Mavacamten Treatment in Hypertrophic Cardiomyopathy
Sehnert emphasizes that mavacamten treatment benefits were present in both patients with sarcomere mutation positive HCM and sarcomere mutation negative HCM.
Data Show Effect of Dietary Sodium Reduction on Blood Pressure Was Comparable to First-Line Medication
Clinically meaningful lowering of blood pressure through reduction in dietary sodium was achieved safely and rapidly in 1 week in a middle-aged and elderly cohort.
Data Show Lepodisiran Was Well Tolerated, Substantially Lowered Lipoprotein (a)
Elevated Lp(a), which was previously untreatable, may become treatable in the near future, according to the study investigator.
Data Show Benefit of Intensive Blood Pressure Reduction Is Consistent in East Asian Population With Hypertension, High Cardiovascular Risk
The SPRINT trial was the first to demonstrate the benefit of further reduction in blood pressure, but it included a limited Asian population and excluded patients with diabetes or history of stroke.
SELECT Trial Data Show Benefit of Semaglutide in Patients With Obesity
The SELECT trial expands on existing literature that have shown safety and cardiovascular benefit in individuals with diabetes to now also show benefit in obesity.
Cardiovascular-Kidney-Metabolic Syndrome Requires a Collaborative Approach to Treatment
The American Heart Association published a statement describing the cardiovascular-kidney-metabolic (CKM) construct, specifically highlighting treatment challenges for CKM syndrome.
Expert: Black Students Face Unique Challenges When Entering, Considering Pharmacy Residency Programs
Experts discuss challenges and recommendations for addressing diversity, equity, and inclusion in pharmacy programs for minority students.
Studies Show Association Between Regular Cannabis Use, Heart Failure
Regular usage of cannabis may increase the risk of heart failure, stroke, or heart attack, even after adjusting for other cardiovascular disease risk factors.
The Ketogenic Diet Could Be an Effective Lifestyle Approach to Manage Advanced-Stage Chronic Kidney Disease, Diabetes
A low carbohydrate diet plus a sodium glucose contransporter-2 (SGLT2) inhibitor was found to be safe and effective for weight loss and glycemic control in patients with diabetes and chronic kidney disease.
Benefits, Mechanisms of SGLT2 Inhibitors in Diabetic Kidney Disease, Other Communities
Although SGLT2 inhibitors are not a cure of diabetic kidney disease, this treatment can help reduce the risk and manage the disease either alone or with complementary therapies.
Systemic Issues Contribute to Health Inequities in LGBTQ+ Community
Deep-rooted discrimination and stigma can contribute to stressors that worsen disease progression and access to care, according to experts.
Improving Care for Patients with Kidney Disease Who Are Pregnant, Undergoing Dialysis
Other than dialysis, Shah notes that patients with kidney disease who are pregnant can receive either nifedipine or labetalol to control blood pressure.
Novel Biomarkers, Diagnostic Approaches for Subtyping Bone Turnover, Improving Patient Outcomes
Nickolas also describes how the use of novel imaging technologies, microRNA, and transcriptomics help experts better understand underlying pathogenesis of ROD.
New Weight Loss Drugs May Have Cardiorenal Benefits for Patients with Kidney Disease
Understanding the mechanisms leading to weight loss could help identify potential benefits for cardiorenal health in patients with chronic kidney disease.
Common Medications for Diabetic Kidney Disease May Be Linked to Increased Risk of Hyperkalemia
Sodium-glucose cotransporter-2 inhibitors and sodium zirconium cyclosilicate may be paired with these kidney disease medications to reduce high serum potassium.
Exercise May Reduce Mortality Among Patients on Dialysis, But Low Compliance Makes Concrete Recommendations Difficult
Exercise has the potential to improve physical performance and fitness at the very least, but a multidisciplinary intervention may work better for patients with chronic kidney disease.
Navigating Medication Challenges in Kidney Disease, Updating Prior Drug Dosing Consensus
Awdishu describes the implementation of new equations to accurately drug dose in patients as well as provide updated guidance on the dosing of older medications.
Various Cancer Types, Drugs May Cause Thrombotic Microangiopathy, Impact Kidney Health
Leung discusses that various cancer types and drugs can cause thrombotic microangiopathy and impact kidney health and the renal complications connected to hematologic malignancies.
Expert: ‘We Can Do Better’ to Assess Risk of Acute Kidney Injury
Nephrotoxic care can be improved with better risk score assessment and provider education.
Machine Learning Models Can Improve Efforts to Offer Dynamic, Precise Kidney Care
Improvements in AI could change the way pharmacists and providers interact with, and care for, patients.
Precision Medicine, Biomarkers, Advancements in Chronic Kidney Disease Treatment
Coca notes the importance of precision medicine in CKD risk assessment and describes the potential impact multiple therapies can have on future CKD prediction and treatment in the future.
Non-Coding RNA, Other Therapeutics Can Impact Acute Kidney Injury Treatment, Recovery
The principal investigator of the Centre for Cardiovascular Science at the University of Edinburgh notes that enhancing endogenous repair can lead to a breakthrough in AKI treatment.
Hyperkalemia Recurrence in Patients With CKD Contributes to Increased Health Care Resource Utilization, Cost
The increased costs for patients with recurrent hyperkalemia were driven by the increased inpatient medical cost of additional time spent in the hospital following recurrence.
Patients With CKD, Hyperkalemia Have Higher Rates of Major Adverse Cardiovascular Events
An analysis of the REVOLUTIONIZE II study data showed that there is an unmet need for long-term outpatient treatment of hyperkalemia in patients with CKD.
Implantable Artificial Kidneys, An Alternative Treatment Method for Kidney Disease
Outside of dialysis and transplantations, implantable artificial kidneys present an additional option for treating kidney disease, according to an expert.
5 Key Sessions, Interviews at ASN 2023 Kidney Week Annual Meeting
Pharmacy Times will be at the American Society for Nephrology’s (ASN) 2023 Kidney Week Annual Meeting in Philadelphia, Pennsylvania, from November 2 to 5.
